All In MedTech

FDA Clearance Tracker · P130026-S070

TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 4, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 4, 2021

Approved

Time to decision

217 days

Received Apr 1, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P130026-S070
Device name
TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
Applicant location
St. Paul, MN
Received
Apr 1, 2021
Decided
Nov 4, 2021
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P130026

Device type

Device class
Class III

Every decision under product code OAE

FDA's approval statement

As written in FDA's record.

Approval for the TactiCath Contact Force Ablation Catheter, Sensor Enabled. The device is indicated for use in cardiac electrophysiology mapping and for the treatment of drug refractory recurrent symptomatic, paroxysmal, and persistent atrial fibrillation, when used in conjunction with a compatible RF generator and three-dimensional mapping system.

Source documents

Other decisions for St Jude Medical

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.